9 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $259M | -$40M | 38.3% | -11.3% | -$26M | $59M | $57M |
| 2024 | $183M | -$76M | 38.5% | -25.9% | -$26M | $75M | $91M |
| 2023 | $353M | -$31M | 26.2% | -8.6% | $41M | $120M | $134M |
| 2022 | $614M | -$43M | 19.4% | -10.1% | -$118M | $99M | $129M |
| 2021 | $981M | $22M | 20.9% | 1.5% | -$44M | $114M | $230M |
| 2020 | $986M | $35M | 20.7% | 2.7% | $11M | $9M | $348M |
| 2019 | $835M | $83M | 25.3% | 10.4% | $57M | — | $259M |
| 2018 | $530M | $49M | 25.8% | 10.0% | $100M | — | $210M |
| 2017 | — | $26M | — | — | $33M | — | $56M |
How the market has priced ZEPP against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Zepp Health Corp's revenue has declined 23.5% per year. These are computed facts, not advice.
As of FY2025, Zepp Health Corp reported $59M of total debt against $57M of cash; operating income covered interest expense -5.1×.
In FY2025, gross margin was 38.3%, operating margin -11.3%, and net margin -15.5%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.